Weekly versus daily leflunomide

Among the most common chronic conditions needing chronic drug therapy are chronic rheumatic diseases, diabetes mellitus,hypertension, depression, psychosis, inflammatory bowel diseases, multiple sclerosis, coronary vascular disease, dyslipidemia and also chronic rheumatic disorders are among. Most researchers and pharmaceutical companies are constantly trying to develop new drugs with more specific measures based on the pathophysiology of the disease in question. Finding an ideal approach in practice guidelines with minimum adverse drug effects is optimum. Post-drug effects deal with the biological effects of a medicine lasting longer than expected from its pharmacological half-life. This could be more evident in many drugs,including hydroxychloroquine, methotrexate, leflunomide, dexamethasone, fluoxetine, and other lipid lowering drugs. This effect not only maintains the therapeutic effect of the drugs, but also reduces the side effects. Leflunomide is an immunomodulatory antirheumatic and disease-modifying drug that is used to treat rheumatoid arthritis as well as other inflammatory arthritis (namely psoriatic arthritis) by inhibiting the synthesis of pyrimidine. Due to the metabolite of leflunomide in the body and the long half-life of this drug, it is possible to prescribe this drug on a weekly basis. Study results have indicated that weekly administration of leflunomide has advantages over daily administration, such as the same therapeutic effect, ease of administration, lower cost of treatment, fewer side effects of medication, and more patient compliance. Thus, based on the results, it can be recommended that leflunomide be administered weekly.